News Video | Policy | GPs | Hospitals | Medical | Mental Health | Welfare | Search

 

Pfizer New Zealand Bextra Advisory


11 April 2005

PFIZER NEW ZEALAND BEXTRA ADVISORY

Pfizer New Zealand will voluntarily suspend the marketing and distribution of Bextra and withdraw the product to pharmacy level, following a request from the regulator Medsafe.

Pfizer New Zealand general Manager Mark Crotty said Medsafe requested the voluntary suspension following similar actions in the US and EU, to allow further review of the overall benefit: risk of Bextra. Pfizer New Zealand is complying with this request to ensure consistency with other markets.

“After discussions with Medsafe, we are advising patients to seek a non-urgent appointment with their doctor to discuss stopping treatment of Bextra”

“This is not a recall to patient level.”

Last week the US FDA informed Pfizer Inc that, in the agency’s view, Bextra’s cardiovascular risk could not be differentiated from other NSAIDs. The agency has concluded that the additional increased risk of rare but serious skin reactions (SCAR) associated with Bextra, already described in its label, warrants its withdrawal.

Pfizer Inc respectfully disagrees with the FDA’s position regarding the overall risk/benefit of Bextra, however, in deference to the agency’s views the company agreed to suspend sales of the medicine in the USA pending further discussions with the FDA.

Bextra is available in New Zealand for the treatment of the signs and symptoms of osteoarthritis and rheumatoid arthritis, and was taken by approximately 1500 patients prior to the initiation of the review of the COX-2 inhibitor class in December 2004. There is currently precautionary advice in the prescribing information and consumer medicine information regarding the risk of developing serious cutaneous adverse reactions when taking Bextra.

Pfizer New Zealand has set up an information line for patients to contact the company for further information on (0800) 734 937.

ENDS

© Scoop Media

 
 
 
Culture Headlines | Health Headlines | Education Headlines

 
Howard Davis Article: A Musical Axis - Brahms, Wagner, Sibelius

Brahms' warm and exquisitely subtle Symphony No. 3 in F major, Wagner's irrepressibly sentimental symphonic poem Siegfried Idyll, and Sibelius' chilling and immensely challenging Violin Concerto in D minor exemplify distinct stages of development in a tangled and convoluted series of skirmishes that came to define subsequent disputes about the nature of post-Romantic orchestral writing well into the following century. More>>

ALSO:

Scoop Review Of Books: A Pale Ghost Writer

Reviewed by Ruth Brassington, Richard Flanagan's new novel is about a novelist hastily ghost-writing the biography of a crook about to go to trial. The reader is kept on a cliff-edge, as the narrator tries to get blood out of his stone man. More>>

Negotiations Begin: Equal Conditions For Men & Women In Professional Football

The trade union representing New Zealand's professional footballers has initiated bargaining for an agreement securing equal terms and conditions for men and women. If negotiated, it will be the first agreement of its kind in the world. More>>

ALSO:


New Zealand Wars Commemoration: Witi Ihimaera's Sleeps Standing Moetū

The second of several articles to mark Rā Maumahara, remembering the New Zealand Land Wars. The first was a Q&A with Vincent O’Malley, author of The Great War for New Zealand: Waikato 1800–2000. More>>

ALSO:


Howard Davis Review: Conflict & Resistance - Ria Hall's Rules of Engagement

From the aftermath of war through colonisation to her own personal convictions, Hall's new CD addresses current issues and social problems on multiple levels, confirming her position as a polemical and preeminent voice on the indigenous NZ music scene. More>>

 
 
 
 
 

LATEST HEADLINES

  • CULTURE
  • HEALTH
  • EDUCATION
 
 
  • Wellington
  • Christchurch
  • Auckland